Skip to main content
Top
Published in: Journal of Gastrointestinal Cancer 2/2022

08-03-2021 | Portal Hypertension | Original Research

The Cook Score: A Novel Assessment for the Prediction of Liver-Associated Clinical Events in a Diverse Population

Authors: Bashar M. Attar, Ishaan Vohra, Yuchen Wang, Rohit Agrawal, Hemant Mutneja, Vatsala Katiyar, Muhammad Arslan Baig, Sachit Sharma, Harishankar Gopakumar, Krishna Rekha Moturi, Prashant Lingamaneni, Zohaib Haque, Seema Gandhi

Published in: Journal of Gastrointestinal Cancer | Issue 2/2022

Login to get access

Abstract

Background and Aims

Transient elastography (TE) provides accurate quantification of liver fibrosis. Its usefulness could be significantly amplified in terms of predicting liver-associated clinical events (LACE). Our aim was to create a model that accurately predicts LACE by combining the information provided by TE with other variables in patients with chronic liver disease (CLD).

Methods

We retrospectively reviewed the electronic medical records of patients who underwent liver elastography, at John H. Stroger Hospital in Cook County, Chicago, IL. The incidences of LACE were documented including decompensation of CLD, new hepatocellular carcinoma, and liver-associated mortality. Significant predicting factors were identified through a forward stepwise Cox regression model. We used the beta-coefficients of these risk factors to construct the Cook Score for prediction of LACE. Receiver-operating characteristic (ROC) curves were plotted for Cook Score to evaluate its efficiency in prediction, in comparison with MELD-Na Score and FIB-4 Score.

Results

A total of 3097 patients underwent liver elastography at our institution. Eighty-eight LACE were identified. Age (hazard ratio (HR) 1.04, p = 0.002), aspartate aminotransferase to alanine aminotransferase ratio (HR 2.61, p < 0.001), platelet count (HR 0.98, p < 0.001), international normalized ration (INR) (HR 17.80, p < 0.001), and liver stiffness measurement (HR1.04, p < 0.001) were identified as significant predictors. The Cook Score was constructed with two optimal cut-off points to stratify patients into low-, intermediate-, and high-risk groups for LACE. The Cook Score proved superior than MELD-Na Score and FIB4 Score in predicting LACE with an area under curve of 0.828.

Conclusion

This novel score based on a large robust sample would provide accurate prediction of prognosis in patients with chronic liver disease and guide individualized surveillance strategy once validated with future studies.
Literature
1.
go back to reference Kim BK, Fung J, Yuen MF, et al. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol. 2013;19(12):1890–900.CrossRef Kim BK, Fung J, Yuen MF, et al. Clinical application of liver stiffness measurement using transient elastography in chronic liver disease from longitudinal perspectives. World J Gastroenterol. 2013;19(12):1890–900.CrossRef
2.
go back to reference Liang XE, Chen YP. Clinical application of vibration controlled transient elastography in patients with chronic hepatitis B. J Clin Transl Hepatol. 2017 28;5(4):368–375. Liang XE, Chen YP. Clinical application of vibration controlled transient elastography in patients with chronic hepatitis B. J Clin Transl Hepatol. 2017 28;5(4):368–375.
3.
go back to reference Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRef Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–82.CrossRef
4.
go back to reference Rincon D, Lo Iacono O, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther. 2007;25:841–8.CrossRef Rincon D, Lo Iacono O, Ripoll C, et al. Prognostic value of hepatic venous pressure gradient for in-hospital mortality of patients with severe acute alcoholic hepatitis. Aliment Pharmacol Ther. 2007;25:841–8.CrossRef
5.
go back to reference Garg H, Kumar A, Garg V, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-onchronic liver failure. J Gastroenterol Hepatol. 2013;28:1361–7.CrossRef Garg H, Kumar A, Garg V, et al. Hepatic and systemic hemodynamic derangements predict early mortality and recovery in patients with acute-onchronic liver failure. J Gastroenterol Hepatol. 2013;28:1361–7.CrossRef
6.
go back to reference Ripoll C, Banares R, Rincon D, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology. 2005;42:793–801.CrossRef Ripoll C, Banares R, Rincon D, et al. Influence of hepatic venous pressure gradient on the prediction of survival of patients with cirrhosis in the MELD Era. Hepatology. 2005;42:793–801.CrossRef
7.
go back to reference Kim TY, Lee JG, Sohn JH, et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis. Yonsei Med J. 2016;57:138–45.CrossRef Kim TY, Lee JG, Sohn JH, et al. Hepatic venous pressure gradient predicts long-term mortality in patients with decompensated cirrhosis. Yonsei Med J. 2016;57:138–45.CrossRef
8.
go back to reference European Association for Study of Liver; Association Latino-Americana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64. European Association for Study of Liver; Association Latino-Americana para el Estudio del Higado. EASL-ALEH Clinical Practice Guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–64.
9.
go back to reference de Franchis R, Faculty BVI. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRef de Franchis R, Faculty BVI. Expanding consensus in portal hypertension: report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63:743–52.CrossRef
10.
go back to reference Chen YP, Liang XE. Non-invasive assessment of liver fibrosis: reduce or substitute the need for liver biopsy? Liver Int. 2015;35:2483.CrossRef Chen YP, Liang XE. Non-invasive assessment of liver fibrosis: reduce or substitute the need for liver biopsy? Liver Int. 2015;35:2483.CrossRef
11.
go back to reference Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hep Intl. 2013;7:356–68.CrossRef Chen YP, Peng J, Hou JL. Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. Hep Intl. 2013;7:356–68.CrossRef
12.
go back to reference Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016;13:402–11.CrossRef Friedrich-Rust M, Poynard T, Castera L. Critical comparison of elastography methods to assess chronic liver disease. Nat Rev Gastroenterol Hepatol. 2016;13:402–11.CrossRef
13.
go back to reference Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61:1851–9.CrossRef Kim MN, Kim SU, Kim BK, et al. Increased risk of hepatocellular carcinoma in chronic hepatitis B patients with transient elastography-defined subclinical cirrhosis. Hepatology. 2015;61:1851–9.CrossRef
14.
go back to reference Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45:1290–7.CrossRef Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology. 2007;45:1290–7.CrossRef
15.
go back to reference Castéra L, Le Bail B, Roudot-Th, Oraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59–68. Castéra L, Le Bail B, Roudot-Th, Oraval F, et al. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59–68.
16.
go back to reference Kazemi F, Kettaneh A, N ’ Kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45:230–5. Kazemi F, Kettaneh A, N ’ Kontchou G, et al. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45:230–5.
17.
go back to reference Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci. 1999;44:1249–53.CrossRef Giannini E, Botta F, Fasoli A, et al. Progressive liver functional impairment is associated with an increase in AST/ALT ratio. Dig Dis Sci. 1999;44:1249–53.CrossRef
18.
go back to reference Assy N, Minuk GY. Serum aspartate but alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenerol. 2000;95:1545–50.CrossRef Assy N, Minuk GY. Serum aspartate but alanine aminotransferase levels help to predict the histological features of chronic hepatitis C viral infections in adults. Am J Gastroenerol. 2000;95:1545–50.CrossRef
19.
go back to reference Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96:3142–6.CrossRef Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol. 2001;96:3142–6.CrossRef
20.
go back to reference Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Gastroenterology. 1988;95:734–9.CrossRef Williams ALB, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Gastroenterology. 1988;95:734–9.CrossRef
22.
go back to reference Castéra L, Le Bail B, Roudot-Thoraval F, Bernard PH, Foucher J, Merrouche W, Couzigou P, de Lédinghen V. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59–68.CrossRef Castéra L, Le Bail B, Roudot-Thoraval F, Bernard PH, Foucher J, Merrouche W, Couzigou P, de Lédinghen V. Early detection in routine clinical practice of cirrhosis and oesophageal varices in chronic hepatitis C: comparison of transient elastography (FibroScan) with standard laboratory tests and non-invasive scores. J Hepatol. 2009;50:59–68.CrossRef
23.
go back to reference Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, Grando-Lemaire V, Trinchet JC, Beaugrand M. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther. 2008;28:1102–10.CrossRef Lemoine M, Katsahian S, Ziol M, Nahon P, Ganne-Carrie N, Kazemi F, Grando-Lemaire V, Trinchet JC, Beaugrand M. Liver stiffness measurement as a predictive tool of clinically significant portal hypertension in patients with compensated hepatitis C virus or alcohol-related cirrhosis. Aliment Pharmacol Ther. 2008;28:1102–10.CrossRef
24.
go back to reference Kazemi F, Kettaneh A, N’kontchou G, Pinto E, Ganne-Carrie N, Trinchet JC, Beaugrand M. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45:230–235. Kazemi F, Kettaneh A, N’kontchou G, Pinto E, Ganne-Carrie N, Trinchet JC, Beaugrand M. Liver stiffness measurement selects patients with cirrhosis at risk of bearing large oesophageal varices. J Hepatol. 2006;45:230–235.
25.
go back to reference Kim BK, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, Lee KS, Chon CY, Kim do Y. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol. 2010;105:1382–1390. Kim BK, Han KH, Park JY, Ahn SH, Kim JK, Paik YH, Lee KS, Chon CY, Kim do Y. A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol. 2010;105:1382–1390.
26.
go back to reference Stafylidou M, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology. 2019. Stafylidou M, et al. Performance of Baveno VI and expanded Baveno VI criteria for excluding high-risk varices in patients with chronic liver diseases: a systematic review and meta-analysis. Clinical Gastroenterology and Hepatology. 2019.
27.
go back to reference Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology. 2008;75(Suppl 1):1–12.CrossRef Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology. 2008;75(Suppl 1):1–12.CrossRef
28.
go back to reference Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRef Masuzaki R, Tateishi R, Yoshida H, Goto E, Sato T, Ohki T, Imamura J, Goto T, Kanai F, Kato N, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRef
29.
go back to reference Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRef Masuzaki R, Tateishi R, Yoshida H, et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology. 2009;49:1954–61.CrossRef
30.
go back to reference Adeel AB, Yanjie R, Vincent LR, III, Tamar HT, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to predict clinical outcomes in Hepatitis C virus-infected persons: results from ERCHIVES, Clinical Infectious Diseases. 2017;65(1):64–72. Adeel AB, Yanjie R, Vincent LR, III, Tamar HT, Kaplan DE. Comparing Child-Pugh, MELD, and FIB-4 to predict clinical outcomes in Hepatitis C virus-infected persons: results from ERCHIVES, Clinical Infectious Diseases. 2017;65(1):64–72.
Metadata
Title
The Cook Score: A Novel Assessment for the Prediction of Liver-Associated Clinical Events in a Diverse Population
Authors
Bashar M. Attar
Ishaan Vohra
Yuchen Wang
Rohit Agrawal
Hemant Mutneja
Vatsala Katiyar
Muhammad Arslan Baig
Sachit Sharma
Harishankar Gopakumar
Krishna Rekha Moturi
Prashant Lingamaneni
Zohaib Haque
Seema Gandhi
Publication date
08-03-2021
Publisher
Springer US
Published in
Journal of Gastrointestinal Cancer / Issue 2/2022
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-021-00620-2

Other articles of this Issue 2/2022

Journal of Gastrointestinal Cancer 2/2022 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.